HighTower Advisors’s Nephros NEPH Stock Holding History

HighTower Advisors’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$222K	Hold	59,710	–	–	﹤0.01%	3474
2026 Q2	$213K	Hold	59,710	–	–	﹤0.01%	3496
2026 Q1	$178K	Hold	59,710	–	–	﹤0.01%	3524
2025 Q4	$291K	Buy	59,710 +4,000	+7%	+$20.4K	﹤0.01%	3070
2025 Q3	$264K	Sell	55,710 -166	-0.3%	-$652	﹤0.01%	3152
2025 Q2	$229K	Buy	55,876 +166	+0.3%	+$443	﹤0.01%	3166
2025 Q1	$95.8K	Hold	55,710	–	–	﹤0.01%	3369
2024 Q4	$81.9K	Sell	55,710 -1,500	-3%	-$2.28K	﹤0.01%	3405
2024 Q3	$98K	Hold	57,210	–	–	﹤0.01%	3320
2024 Q2	$121K	Sell	57,210 -1,000	-2%	-$2.16K	﹤0.01%	3164
2024 Q1	$127K	Buy	58,210 +1,500	+3%	+$4.76K	﹤0.01%	3099
2023 Q4	$196K	Hold	56,710	–	–	﹤0.01%	3018
2023 Q3	$83K	Hold	56,710	–	–	﹤0.01%	3139
2023 Q2	$89K	Buy	56,710 +1,000	+2%	+$1.48K	﹤0.01%	3092
2023 Q1	$60K	Hold	55,710	–	–	﹤0.01%	3027
2022 Q4	$64K	Hold	55,710	–	–	﹤0.01%	2994
2022 Q3	$51K	Hold	55,710	–	–	﹤0.01%	2878
2022 Q2	$85K	Hold	55,710	–	–	﹤0.01%	2823
2022 Q1	$245K	Hold	55,710	–	–	﹤0.01%	2680
2021 Q4	$328K	Hold	55,710	–	–	﹤0.01%	2426
2021 Q3	$488K	Hold	55,710	–	–	﹤0.01%	2066
2021 Q2	$565K	Hold	55,710	–	–	﹤0.01%	1985
2021 Q1	$370K	Hold	55,710	–	–	﹤0.01%	2153
2020 Q4	$478K	Buy	55,710 +12,500	+29%	+$84.4K	﹤0.01%	1662
2020 Q3	$313K	Hold	43,210	–	–	﹤0.01%	1813
2020 Q2	$362K	Hold	43,210	–	–	﹤0.01%	1624
2020 Q1	$273K	Hold	43,210	–	–	﹤0.01%	1623
2019 Q4	$430K	Buy	+43,210	New	+$385K	﹤0.01%	1513

Other funds holding NEPH

Massachusetts Institute of Technology Cambridge, Massachusetts $695M AUM 43.77% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Meritage Group San Francisco, California $2.78B AUM 9.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Bard Associates Chicago, Illinois $431M AUM 30.93% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

HighTower Advisors's NEPH Position: Q3 2026 in Review

HighTower Advisors held its Nephros (NEPH) position steady in Q3 2026 at 59,710 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3474.

HighTower Advisors first reported a position in NEPH in Q4 2019 and has held it in 28 quarters since. The position peaked at $565K in Q2 2021. 26 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

HighTower Advisors held 59,710 shares of Nephros worth $222K as of Q3 2026.
HighTower Advisors left its Nephros share count unchanged in Q3 2026.
Nephros made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3474 holding.
HighTower Advisors first reported a position in Nephros in Q4 2019 and has held it in 28 quarters since.
HighTower Advisors's Nephros position peaked at $565K in Q2 2021.
26 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.